Pumpkin derived compounds to treat Type 2 diabetes
Lead Participant:
EMINATE LIMITED
Abstract
This part TSB funded feasibilty project is designed to assess the commercial potential for biologically active compounds derived from members of the Cucurbitae plant family to help naturally treat some of the most common symptoms of Type 2 diabetes.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| EMINATE LIMITED | £70,225 | £ 45,646 |
Participant |
||
| UNIVERSITY OF NOTTINGHAM | £29,695 | £ 29,695 |
| INNOVATE UK |
People |
ORCID iD |
| Andrew Bonser (Project Manager) |